Meeting
2018 Gastrointestinal Cancers Symposium
Results of neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fuluorouracil for advanced esophageal cancer.
Authors
Manabu Emi
Hiroshima University, Hiroshima, Japan
Manabu Emi , Yoichi Hamai , Yuta Ibuki , Morihito Okada
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
R000002555
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 171)
DOI
10.1200/JCO.2018.36.4_suppl.171
Abstract #
171
Poster Bd #
L9
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A phase II trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer (KDOG 0501-P2).
First Author: Katsuhiko Higuchi
Poster
2016 Gastrointestinal Cancers Symposium
S-1 in combination with docetaxel and oxaliplatin (DOS) every 2 weeks (DOS2w) or every 3 weeks (DOS3w) in patients with advanced gastro-esophageal adenocarcinoma (aGEA): Final results of 2 parallel phase I studies.
First Author: Camilla Qvortrup
Poster
2015 Gastrointestinal Cancers Symposium
A phase I/II study of definitive chemoradiotherapy with docetaxel, nedaplatin, and 5-fluorouracil (DNF-R) for advanced esophageal cancer.
First Author: Yasushi Sato
Poster
2015 Gastrointestinal Cancers Symposium
A phase I/II study of divided-dose docetaxel, cisplatin, and fluorouracil (DCF) for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
First Author: Toshiyasu Ojima